Claims
- 1. A method for preventing or limiting restenosis in a mammal having undergone a non-bypass invasive procedure which comprises orally or parentally administering on a daily basis at a predetermined time to said mammal an effective amount of a dopamine-potentiating/prolactin-reducing compound for preventing or limiting restenosis in said mammal.
- 2. The method of claim 1 wherein said dopamine potentiating/prolactin-reducing compound is bromocriptine.
- 3. The method of claim 2 which further comprises:
- orally or parentally administering on a daily basis at a second predetermined time to said mammal an effective amount of a prolactin-enhancing compound, wherein said prolactin-enhancing compound is selected from the group consisting of prolactin, melatonin, haloperidol, pimozide, phenothiazine, domperidone, sulpiride, chlorpromazine, pargyline, synthetic morphine analogs, methadone, antiemetics, estrogens, tryptophan, 5-hydroxytryptophan, fluoxetine, and dexfenfluramine.
- 4. The method of claim 3 wherein said prolactin-enhancing compound is melatonin and wherein said melatonin is administered in an amount between about 1 and about 10 mg per day.
- 5. The method of claim 3 wherein said prolactin enhancing compound is fluoxetine and wherein said fluoxetine is administered in an amount between about 1 and about 20 mg per day.
- 6. The method of claim 3 wherein said prolactin enhancing compound is dexfenfluramine and wherein said dexfenfluramine is administered in an amount between about 1 and about 30 mg per day.
- 7. The method of claim 1 wherein said amount of dopamine-potentiating/prolactin-reducing compound is effective for inhibiting the proliferation of vascular smooth muscle cells in a mammal in need of such treatment.
- 8. A method for reducing or eliminating angina pectoris or amaurosis fugax in a mammal having undergone a non-bypass invasive procedure which comprises orally or parenterally administering on a daily basis at a predetermined time to said mammal an effective amount of a dopamine-potentiating/prolactin-reducing compound for reducing or eliminating angina pectoris or amaurosis fugax in said mammal.
- 9. The method of claim 8 wherein said dopamine potentiating/prolactin-reducing compound is bromocriptine.
- 10. The method of claim 9 which further comprises:
- orally or parenterally administering on a daily basis at a second predetermined time to said mammal an effective amount of a prolactin-enhancing compound, wherein said prolactin-enhancing compound is selected from the group consisting of prolactin, melatonin, haloperidol, pimozide, phenothiazine,-domperidone, sulpiride, chlorpromazine, pargyline, synthetic morphine analogs, methadone, antiemetics, estrogens, tryptophan, 5-hydroxytryptophan, fluoxetine, and dexfenfluramine.
- 11. The method of claim 10 wherein said prolactin-enhancing compound is melatonin and wherein said melatonin is administered in an amount between about 1 and about 10 mg per day.
- 12. The method of claim 10 wherein said prolactin enhancing compound is fluoxetine and wherein said fluoxetine is administered in an amount between about 1 and about 20 mg per day.
- 13. The method of claim 10 wherein said prolactin enhancing compound is dexfenfluramine and wherein said dexfenfluramine is administered in an amount between about 1 and about 30 mg per day.
- 14. A method for inhibiting proliferation of vascular smooth muscle cells in a mammal having undergone a non-bypass invasive procedure which comprises orally or parenterally administering on a daily basis at a predetermined time to said mammal an effective mount of a dopamine-potentiating/prolactin-reducing compound for inhibiting the proliferation of vascular smooth muscle cells in said mammal.
- 15. The method of claim 14 wherein said mammal has undergone a on-bypass invasive procedure.
- 16. The method of claim 14 wherein said dopamine potentiating/prolactin-reducing compound is bromocriptine.
- 17. The method of claim 14 which further comprises:
- orally or parenterally administering on a daily basis at a second predetermined time to said mammal an effective amount of a prolactin-enhancing compound elected from the group consisting of prolactin, melatonin, haloperidol, pimozide, phenothiazine, domperidone, sulpiride, chlorpromazine, pargyline, synthetic morphine analogs, methadone, antiemetics, estrogens, tryptophan, 5-hydroxytryptophan, fluoxetane, and dexfenfluramine.
- 18. The method of claim 17 wherein said prolactin-enhancing compound is melatonin and wherein said melatonin is administered in an amount between about 1 and about 10 mg per day.
- 19. The method of claim 17 wherein said prolactin enhancing compound is fluoxetine and wherein said fluoxetane is administered in an amount between about 1 and about 20 mg per day.
- 20. The method of claim 17 wherein said prolactin enhancing compound is dexfenfluramine and wherein said dexfenfluramine is administered in an amount between about 1 and about 30 mg per day.
Parent Case Info
This is a continuation, division, of application Ser. No. 08/455,354, filed May 31, 1995, now U.S. Pat. No. 5,565,454.
US Referenced Citations (7)
Foreign Referenced Citations (1)
Number |
Date |
Country |
890369 |
Mar 1982 |
BEX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
455354 |
May 1995 |
|